Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
FMS 
Fresenius Medical Care Corporation (FMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: FMS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $30.2
1 Year Target Price $30.2
| 1 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.44% | Avg. Invested days 32 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 14.69B USD | Price to earnings Ratio 18.86 | 1Y Target Price 30.2 |
Price to earnings Ratio 18.86 | 1Y Target Price 30.2 | ||
Volume (30-day avg) 6 | Beta 0.88 | 52 Weeks Range 18.43 - 29.71 | Updated Date 09/16/2025 |
52 Weeks Range 18.43 - 29.71 | Updated Date 09/16/2025 | ||
Dividends yield (FY) 3.15% | Basic EPS (TTM) 1.31 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 3.36% | Operating Margin (TTM) 8.23% |
Management Effectiveness
Return on Assets (TTM) 3.03% | Return on Equity (TTM) 5.72% |
Valuation
Trailing PE 18.86 | Forward PE 9.94 | Enterprise Value 25577053830 | Price to Sales(TTM) 0.75 |
Enterprise Value 25577053830 | Price to Sales(TTM) 0.75 | ||
Enterprise Value to Revenue 1.12 | Enterprise Value to EBITDA 6.88 | Shares Outstanding 586827008 | Shares Floating 208687381 |
Shares Outstanding 586827008 | Shares Floating 208687381 | ||
Percent Insiders - | Percent Institutions 8.01 |
Upturn AI SWOT
Fresenius Medical Care Corporation
Company Overview
History and Background
Fresenius Medical Care was founded in 1996 through the merger of Fresenius AG's dialysis division and National Medical Care. It has grown to become a leading provider of dialysis products and services.
Core Business Areas
- Dialysis Services: Provides dialysis treatment and related services to patients with chronic kidney failure in dialysis centers worldwide.
- Dialysis Products: Develops, manufactures, and distributes a wide range of products for dialysis treatment, including hemodialysis machines, dialyzers, and related disposables.
- Care Coordination: Offers services to coordinate the overall care of dialysis patients, including medication management and other healthcare services.
Leadership and Structure
Rice Powell is the current CEO of Fresenius Medical Care. The company operates under a divisional structure, with separate segments for dialysis services, dialysis products, and other healthcare services.
Top Products and Market Share
Key Offerings
- Hemodialysis Machines: Fresenius Medical Care is a leading manufacturer of hemodialysis machines used in dialysis centers and hospitals. They hold a significant market share (estimated 35-40%). Competitors include Baxter, Nikkiso and B. Braun.
- Market Share (%): 35,40
- Dialyzers: Fresenius Medical Care produces dialyzers, also known as artificial kidneys, which filter waste products from the blood during dialysis treatment. Competitors include Asahi Kasei Medical and Nipro.
- Market Share (%): 30,35
- Dialysis Clinics: Fresenius owns and operates thousands of dialysis centers globally, providing direct dialysis treatment services. They have competitors such as DaVita Healthcare Partners.
- Market Share (%): 30,35
Market Dynamics
Industry Overview
The dialysis services and products market is driven by the increasing prevalence of chronic kidney disease (CKD) and end-stage renal disease (ESRD). The market is characterized by consolidation and technological advancements in dialysis equipment and therapies.
Positioning
Fresenius Medical Care is one of the largest players in the dialysis market, with a global presence and a vertically integrated business model. Its competitive advantages include its scale, established brand, and comprehensive product and service offerings.
Total Addressable Market (TAM)
The global dialysis market is expected to reach $120 billion USD by 2030. Fresenius Medical Care is positioned as a key player capturing a large portion of this TAM.
Upturn SWOT Analysis
Strengths
- Global presence and extensive network of dialysis centers
- Vertically integrated business model
- Strong brand recognition
- Leading market share in dialysis products and services
- Extensive research and development capabilities
Weaknesses
- Exposure to regulatory changes and reimbursement pressures
- High debt levels
- Dependence on government reimbursement programs
- Geographic concentration in certain markets
- Fluctuations in foreign exchange rates
Opportunities
- Expanding dialysis services in emerging markets
- Developing innovative dialysis technologies
- Acquiring smaller dialysis providers
- Diversifying into related healthcare services
- Capitalizing on the growing prevalence of CKD and ESRD
Threats
- Increasing competition from other dialysis providers
- Downward pressure on reimbursement rates
- Technological disruptions in dialysis treatment
- Changes in government regulations
- Economic downturns
Competitors and Market Share
Key Competitors
- DVA
Competitive Landscape
Fresenius Medical Care faces intense competition from DaVita Healthcare Partners (DVA). Fresenius advantages include its global presence and vertically integrated business model.
Major Acquisitions
NxStage Medical
- Year: 2019
- Acquisition Price (USD millions): 2000
- Strategic Rationale: Expanded Fresenius Medical Care's home dialysis offerings.
Growth Trajectory and Initiatives
Historical Growth: Historically, Fresenius Medical Care has grown through acquisitions and organic expansion of its dialysis services network. However, growth has slowed in recent years due to reimbursement pressures and regulatory challenges.
Future Projections: Future growth is expected to be driven by the increasing prevalence of CKD and ESRD, particularly in emerging markets. Analyst estimates suggest modest revenue growth in the coming years.
Recent Initiatives: Recent strategic initiatives include focusing on cost reduction, improving operational efficiency, and expanding its presence in emerging markets.
Summary
Fresenius Medical Care is a leading dialysis provider facing financial pressures. Despite its global presence, challenges with profitability and debt weigh on the company's performance. Cost reduction and expansion in emerging markets are key to its future growth. The company needs to address regulatory pressures and improve its financial position to enhance shareholder value.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Reports
- Market Research Reports
- SEC Filings
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice. Market share data is estimated. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Fresenius Medical Care Corporation
Exchange NYSE | Headquaters - | ||
IPO Launch date 1996-09-19 | Chair of Management Board & CEO Ms. Helen Giza | ||
Sector Healthcare | Industry Medical Care Facilities | Full time employees 112445 | |
Full time employees 112445 | |||
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products. In addition, the company develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, physician nephrology, ambulant treatment, and other services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics, as well as through local sales forces, independent distributors, dealers, and sales agents. Fresenius Medical Care AG was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.